Key Success Factors in Stomach Cancer Clinical Trials:

Addressing Safety, Efficacy, and Endpoints

INGENŪ CRO

Introduction

Stomach cancer, also known as gastric cancer, is a critical global health concern, ranking as the fifth most common cancer worldwide and the third leading cause of cancer-related deaths.

This whitepaper provides a comprehensive overview of the multifaceted challenges associated with stomach cancer, including its biological, environmental, and psychological contributors. Key topics include advancements in molecular diagnostics, the evolution of treatment strategies such as targeted therapies and immunotherapy, and the significance of regional and genetic disparities in disease prevalence.

Through an exploration of historical perspectives, current therapeutic options, and the latest research developments, this whitepaper aims to equip healthcare professionals, researchers, and stakeholders with actionable insights to improve prevention, diagnosis, and treatment outcomes. With a focus on bridging gaps in care, addressing global disparities, and fostering innovation, it highlights the path forward in the fight against this devastating disease.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Insights on Stomach Cancer

Overview

Stomach cancer, or gastric cancer, is a malignancy originating in the stomach lining, often presenting as adenocarcinoma. It is the fifth most common cancer worldwide and ranks third in cancer-related deaths. Symptoms often remain silent in early stages, leading to late-stage diagnoses. Common symptoms include unexplained weight loss, persistent stomach pain, nausea, and a feeling of fullness after small meals.

Key Characteristics

Stomach cancer is characterized by a combination of environmental, genetic, and epigenetic alterations. Key factors include Helicobacter pylori infection, dietary habits, and hereditary syndromes like Lynch syndrome. Histologically, it can be divided into intestinal and diffuse types based on Lauren's classification.

Historical Perspectives

The understanding of stomach cancer has evolved significantly. Early identification was limited due to diagnostic challenges, but with the advent of endoscopy and advanced imaging, diagnosis improved. By the late 20th century, Helicobacter pylori's role as a carcinogen revolutionized prevention strategies, emphasizing early eradication therapy.

Contributing Factors

1. Biological:

Helicobacter pylori infection remains the strongest biological contributor, linked to chronic inflammation and DNA damage. Additionally, genetic mutations such as CDH1 germline mutations elevate familial risk. Overexpression of oncogenes like HER2 also contributes.

2. Psychological:

Psychological distress, including depression and anxiety, may exacerbate outcomes by influencing immune function and patient adherence to treatment. Emerging research indicates a bidirectional relationship between stress and cancer progression.

3. Environmental:

High intake of smoked, salted, or pickled foods correlates with increased risk, especially in regions like East Asia. Conversely, diets rich in fresh fruits, vegetables, and antioxidants exhibit protective effects. Smoking and alcohol also significantly elevate risk.

4. Evolution Over Time:

While H. pylori eradication and dietary changes have reduced incidence in developed nations, disparities remain in low-income regions. Advances in molecular biology now allow for precise subclassification of tumors for targeted therapies.

Prevalence and Diagnostic Criteria

Prevalence

- Global prevalence in 2023: ~1.03 million cases annually.
- US prevalence: ~26,500 cases diagnosed annually.
- From 2013 to 2023, incidence decreased by ~1.5% annually in developed nations due to better diagnostics and prevention but remains stable in high-risk regions like East Asia.
- Projections for 2033 indicate a continued decline in developed countries but potentially stable or increased rates in developing areas without effective public health interventions.

Advancements in Research

- Development of immunotherapies, such as PD-1 inhibitors (e.g., nivolumab), has transformed the therapeutic landscape.
- Advancements in molecular diagnostics enable tailored treatments based on HER2 expression, mismatch repair deficiency, or Epstein-Barr virus status.
- Artificial intelligence is improving early detection via endoscopic imaging.

Market Analysis

The global stomach cancer treatment market was valued at USD 3.6 billion in 2023, with a projected CAGR of 7.1% from 2024 to 2033, driven by the adoption of targeted therapies and immunotherapies.

Drug Name	Manufacturer	Market Share (%)	Earning Potential (USD)
Keytruda	Merck	35%	$1.26 billion
Herceptin	Roche	25%	$900 million
Opdivo	Bristol Myers	20%	$720 million
Cyramza	Eli Lilly	15%	$540 million
Enhertu	AstraZeneca/Daiichi Sankyo	5%	$180 million

ICD-11 Code 2B72: Malignant Neoplasm of the Stomach

1. Clinical Presentation: Persistent epigastric pain, unexplained weight loss, early satiety, nausea, vomiting, and gastrointestinal bleeding.
2. Endoscopic Findings: Visualization of gastric lesions or masses via gastroscopy.
3. Histopathological Confirmation: Biopsy revealing malignant gastric cells, typically adenocarcinoma.
4. Imaging Studies: CT or MRI scans indicating tumor presence, local invasion, or distant metastasis.
5. Laboratory Tests: Elevated tumor markers such as carcinoembryonic antigen (CEA) or CA 19-9 may support the diagnosis.

Evolution of Criteria Over Time

Historically, stomach cancer diagnosis relied heavily on clinical symptoms and basic imaging, often leading to late-stage detection. The advent of endoscopy in the mid-20th century allowed direct visualization and biopsy of gastric lesions, significantly improving early detection rates. Advancements in imaging modalities, such as CT and MRI, have further enhanced staging accuracy. The integration of molecular diagnostics in recent years has enabled the identification of specific genetic mutations and biomarkers, facilitating personalized treatment approaches.

Impact on Clinical and Research Perspectives

The refinement of diagnostic criteria in ICD-11 emphasizes a comprehensive approach, combining clinical evaluation with advanced diagnostic tools. Clinically, this has led to earlier detection, more accurate staging, and tailored therapeutic strategies, improving patient outcomes. From a research standpoint, the detailed classification supports epidemiological studies, aids in the development of targeted therapies, and enhances the comparability of clinical trial data across different regions and populations.

Epidemiology of Stomach Cancer

Global Prevalence

Stomach cancer, or gastric cancer, is a significant global health burden. It is the fifth most common malignancy worldwide, with approximately 1.03 million new cases diagnosed annually as of 2023. While incidence rates are declining in developed regions such as North America and Europe, they remain alarmingly high in East Asia, particularly in countries like Japan, South Korea, and China. In developing nations, the disease accounts for a disproportionate share of cancer-related deaths due to late-stage detection and limited healthcare infrastructure.

Prevalence by Age

Stomach cancer is rare in individuals under 40, with the majority of cases diagnosed in people aged 60 to 70. The increased risk with age is attributed to cumulative exposure to risk factors such as chronic Helicobacter pylori infection, dietary habits, and genetic changes over time. Aging also correlates with a decline in immune surveillance, which may facilitate tumor growth and progression. Screening programs in high-risk populations, particularly for older adults, have significantly contributed to earlier detection and improved outcomes.

Prevalence by Gender

Men are nearly twice as likely as women to develop stomach cancer, with a male-to-female ratio of approximately 2:1 globally. This disparity is thought to be partly due to hormonal differences, as estrogen appears to have a protective effect against gastric carcinogenesis. Additionally, men are more likely to engage in high-risk behaviors such as smoking and heavy alcohol consumption, which are established contributors to stomach cancer. Despite this, recent data suggest narrowing gender gaps in some populations, possibly reflecting changes in lifestyle and healthcare access.

Prevalence by Race and Ethnicity

Stomach cancer prevalence varies significantly by race and ethnicity, reflecting genetic, environmental, and socioeconomic factors. Asian populations, especially those in Japan, Korea, and China, exhibit the highest rates, driven by dietary habits and a high prevalence of H. pylori infection. In the United States, Hispanic and African American populations have higher stomach cancer rates than Caucasians, which may be linked to disparities in healthcare access, dietary patterns, and genetic predispositions. By contrast, Caucasians in Western countries show lower prevalence, likely due to lifestyle changes and better prevention strategies, such as routine H. pylori eradication.

INGENŪ CRO

Pivotal Endpoints for Stomach Cancer Clinical Trials:
Key Challenges and Solutions

1. Overall Survival (OS)

Correlation to Patient Outcome:

Direct measure of treatment success; reflects long-term effectiveness of interventions.

Challenge:

Requires prolonged follow-up to capture survival data, which can delay clinical trial results. Attrition of participants over time, especially in multi-year studies, can also bias results.

Solution:

Use surrogate endpoints such as progression-free survival (PFS) or tumor response rate (TRR) to provide interim insights. Implement robust patient follow-up systems and digital monitoring tools to minimize attrition.

2. Progression-Free Survival (PFS)

Correlation to Patient Outcome:

Indicates treatment efficacy by measuring time until disease progression.

Challenge:

Imaging variability and subjective interpretation of radiological findings can lead to inconsistencies. Defining "progression" may vary across studies, affecting comparability.

Solution:

Standardize imaging protocols across trial sites using centralized radiology reviews. Train radiologists in RECIST (Response Evaluation Criteria in Solid Tumors) criteria to ensure uniformity in progression assessment.

3. Response Rate (RR)

Correlation to Patient Outcome:

Reflects short-term effectiveness of treatments in reducing tumor size.

Challenge:

Not all reductions in tumor size correlate with long-term benefits like survival. Lack of consensus on what constitutes a meaningful response in heterogeneous tumors like stomach cancer.

Solution:

Combine RR data with OS and PFS to assess holistic treatment benefits. Develop molecular biomarkers to predict which tumor reductions will translate to improved survival outcomes.

NGENŪ CRO

FDA-Approved Treatments for Stomach Cancer

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Keytruda	2017	Merck	PD-1 inhibitor: Blocks the programmed death-1 (PD-1) receptor on T-cells, preventing cancer cells from evading immune detection. This enhances the ability of the immune system to identify and destroy tumor cells.	Improves immune response against tumors, prolonging survival in patients with advanced or metastatic stomach cancer. Particularly effective in patients with high microsatellite instability (MSI-H) or PD-L1 expression.
Herceptin	1998	Roche	HER2 inhibition: Targets and blocks the HER2 receptor, a protein that promotes cell growth in HER2-positive cancers. This prevents proliferation of tumor cells reliant on HER2 signaling.	Significantly improves survival in patients with HER2-positive gastric cancer, especially when combined with chemotherapy. Reduces tumor growth and slows disease progression.
Opdivo	2021	Bristol Myers	PD-1 inhibitor: Functions similarly to Keytruda by inhibiting the PD-1 receptor, restoring T-cell activity to target and destroy tumor cells. Its specificity for different populations complements other immunotherapies.	Extends overall survival in patients with advanced gastric or gastroesophageal junction cancer, particularly in those with PD-L1-positive tumors. Effective in refractory cases.
Cyramza	2014	Eli Lilly	VEGFR2 inhibition: Binds to vascular endothelial growth factor receptor 2 (VEGFR2), blocking angiogenesis (formation of new blood vessels) necessary for tumor growth and metastasis.	Inhibits tumor angiogenesis, reducing tumor blood supply and leading to slower tumor growth. Used in combination with chemotherapy for patients with advanced or metastatic disease.
Enhertu	2022	AstraZeneca/ Daiichi Sankyo	HER2-targeted antibody-drug conjugate (ADC): Combines a HER2-specific antibody with a cytotoxic payload, delivering chemotherapy directly to HER2-expressing cancer cells, sparing healthy tissues.	Effective in HER2-positive metastatic gastric cancer patients who are resistant to prior HER2-targeted therapies. Demonstrates high tumor response rates and improved survival outcomes.

Pivotal Clinical Trials for Top Drugs for Stomach Cancer

Drug Name	NCT Number	Sample Size	Key Findings and Statistical Data
Keytruda	NCT02335411	592	The study demonstrated a median overall survival (OS) of 13.3 months for Keytruda compared to 8.4 months in the placebo group, highlighting its significant survival benefit in patients with PD-L1-positive tumors. Furthermore, durable response rates were observed, with some patients achieving long-term disease control.
Herceptin	NCT01178935	594	Herceptin, combined with chemotherapy, extended progression-free survival (PFS) by 2.7 months (6.7 vs. 4 months) and median OS by 2.5 months compared to chemotherapy alone in HER2-positive gastric cancer patients. It also showed improved tumor shrinkage rates, with overall response rates exceeding 47%.
Opdivo	NCT02569242	493	The trial showed a significant OS improvement of 5.3 months (10.9 vs. 5.6 months) in patients treated with Opdivo compared to placebo in refractory advanced gastric cancer. Subgroup analysis revealed higher efficacy in patients with high PD-L1 expression, reinforcing its role as a targeted immune therapy.
Cyramza	NCT00917384	665	Cyramza extended median OS by 1.4 months (5.2 vs. 3.8 months) as a monotherapy compared to placebo in previously treated gastric cancer patients. Additionally, combination therapy with paclitaxel showed a significant increase in PFS (4.4 vs. 2.9 months), demonstrating its versatility in different therapeutic regimens.
Enhertu	NCT04014075	187	Enhertu exhibited high response rates, with 51% of patients achieving tumor shrinkage, including a complete response in a subset. The study highlighted a median OS of 12.5 months in heavily pretreated HER2-positive metastatic gastric cancer patients, emphasizing its efficacy in overcoming resistance to prior HER2-targeted therapies.

Approved Product Analysis: Keytruda

14.10 Gastric Cancer

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with advanced gastric/GEJ cancer, progressed after ≥2 systemic treatments	Overall Response Rate (ORR)	RECIST v1.1 (BICR assessed)	Every 6-9 weeks for up to 24 months	N=259 (overall population); N=143 (PD-L1 CPS ≥1); N=7 (MSI-H tumors)	ORR for PD-L1 CPS ≥1: 13.3% (95% CI: 8.2, 20.0); 1.4% complete response, 11.9% partial response. DoR ranged from 2.8+ to 19.4+ months, with 26% having responses ≥12 months. For MSI-H tumors: ORR was observed in 4/7 patients (1 complete response), DoR ranged from 5.3+ to 14.1+ months.
Subgroup: PD-L1 CPS ≥1 (143 patients)	Overall Response Rate (ORR), Duration of Response (DoR)	RECIST v1.1 (BICR assessed)	Every 6-9 weeks for up to 24 months	N=143 (55% of total)	ORR: 13.3%. Median DoR: 2.8+ to 19.4+ months. 26% of responders maintained response ≥12 months.
Subgroup: MSI-H tumors (7 patients)	Objective Response Rate (ORR), Duration of Response (DoR)	RECIST v1.1 (BICR assessed)	Every 6-9 weeks for up to 24 months	N=7 (3% of total)	ORR: 57.1% (4/7 patients, including 1 complete response). DoR: 5.3+ to 14.1+ months.

Approved Product Analysis: Herceptin

14.3 Metastatic Gastric Cancer

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Untreated metastatic gastric/GEJ adenocarcinoma (HER2+)	Overall Survival (OS)	Unstratified log-rank test	Updated at one year post-analysis	N=594 (FC: 296; FC+H: 298)	Median OS for FC+H arm: 13.1 months vs. FC arm: 11.7 months. Hazard ratio (HR): 0.80 (95% CI: 0.67, 0.97). Significant improvement in OS (p=0.0038).
Subgroup: FISH+ or IHC3+	OS	Unstratified log-rank test	Exploratory analysis	N=294 (FC: 143; FC+H: 151)	Median OS for FC+H arm: 18.0 months vs. FC arm: 13.2 months. HR: 0.66 (95% CI: 0.50, 0.87). Significant improvement.
Subgroup: FISH+/IHC2+	OS	Unstratified log-rank test	Exploratory analysis	N=160 (FC: 80; FC+H: 80)	Median OS for FC+H arm: 12.3 months vs. FC arm: 10.8 months. HR: 0.78 (95% CI: 0.55, 1.10). No statistically significant difference.
Subgroup: FISH+/IHC 0, 1+	OS	Unstratified log-rank test	Exploratory analysis	N=133 (FC: 71; FC+H: 62)	Median OS for FC+H arm: 8.3 months vs. FC arm: 8.8 months. HR: 1.33 (95% CI: 0.92, 1.92). No significant difference in OS.
HER2+ Overall ITT Population	OS	Unstratified log-rank test	Definitive and Updated Analyses	N=594 (FC: 296; FC+H: 298)	Definitive OS: Median OS for FC+H arm: 13.5 months vs. FC arm: 11.0 months. HR: 0.73 (95% CI: 0.60, 0.91). Significant improvement (p=0.0038).

Approved Product Analysis: Opdivo

14.13 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Advanced/metastatic gastric/GEJ/esophageal adenocarcinoma (all patients)	Overall Survival (OS)	RECIST v1.1, stratified Cox	Minimum follow-up: 12.1 months	N=1581 (OPDIVO+Chemo: 789; Chemo: 792)	Median OS for OPDIVO+Chemo: 13.8 months (95% CI: 12.6, 14.6) vs. Chemo: 11.6 months (95% CI: 10.9, 12.5). HR: 0.80 (95% CI: 0.71, 0.90), p=0.0002.
Subgroup: PD-L1 CPS ≥1	OS, Progression-Free Survival (PFS)	RECIST v1.1, stratified Cox	Minimum follow-up: 12.1 months	N=1096 (OPDIVO+Chemo: 641; Chemo: 655)	Median OS for OPDIVO+Chemo: 14.0 months (95% CI: 12.6, 15.0) vs. Chemo: 11.3 months (95% CI: 10.6, 12.3). HR: 0.77 (95% CI: 0.68, 0.88), p<0.0001. Median PFS: 7.5 vs. 6.9 months, HR: 0.74.
Subgroup: PD-L1 CPS ≥5	OS, PFS	RECIST v1.1, stratified Cox	Minimum follow-up: 12.1 months	N=955 (OPDIVO+Chemo: 473; Chemo: 482)	Median OS for OPDIVO+Chemo: 14.4 months (95% CI: 13.1, 16.2) vs. Chemo: 11.1 months (95% CI: 10.0, 12.1). HR: 0.71 (95% CI: 0.61, 0.83), p<0.0001. Median PFS: 7.7 vs. 6.0 months, HR: 0.68.
Subgroup: PD-L1 CPS <1	OS	RECIST v1.1, stratified Cox	Minimum follow-up: 12.1 months	N=265 (OPDIVO+Chemo: not specified)	Median OS for OPDIVO+Chemo: 13.1 months (95% CI: 9.8, 16.7) vs. Chemo: 12.5 months (95% CI: 10.1, 13.8). HR: 0.85 (95% CI: 0.63, 1.15). Not statistically significant.
Subgroup: PD-L1 CPS <5	OS	RECIST v1.1, stratified Cox	Minimum follow-up: 12.1 months	N=606 (OPDIVO+Chemo: not specified)	Median OS for OPDIVO+Chemo: 12.4 months (95% CI: 10.6, 14.3) vs. Chemo: 12.3 months (95% CI: 11.0, 13.2). HR: 0.94 (95% CI: 0.78, 1.14). Not statistically significant.
All Patients (ORR and DoR analysis)	Objective Response Rate (ORR), Duration of Response (DoR)	RECIST v1.1 (BICR)	Median follow-up of 12.1 months	ORR: OPDIVO+Chemo: 47%; Chemo: 37%	ORR for OPDIVO+Chemo: 47% (10% complete response) vs. Chemo: 37% (7% complete response). Median DoR: OPDIVO+Chemo: 8.5 months vs. Chemo: 6.9 months.
Subgroup: PD-L1 CPS ≥5 (ORR and DoR analysis)	ORR, DoR	RECIST v1.1 (BICR)	Median follow-up of 12.1 months	ORR: OPDIVO+Chemo: 50%; Chemo: 38%	ORR for OPDIVO+Chemo: 50% (12% complete response) vs. Chemo: 38% (7% complete response). Median DoR: OPDIVO+Chemo: 9.5 months vs. Chemo: 6.9 months.

Approved Product Analysis: Cyramza

Gastric Cancer

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Locally advanced/metastatic gastric or GEJ adenocarcinoma (CYRAMZA + BSC vs. Placebo)	Overall Survival (OS)	Stratified log-rank	Study duration: 1–34 doses	N=355 (CYRAMZA: 238; Placebo: 117)	Median OS: 5.2 months (95% CI: 4.4, 5.7) for CYRAMZA vs. 3.8 months (95% CI: 2.8, 4.7) for placebo. HR: 0.78 (95% CI: 0.60, 0.998), p=0.047.
	Progression-Free Survival (PFS)	Stratified log-rank	Study duration: 1–34 doses	N=355 (CYRAMZA: 238; Placebo: 117)	Median PFS: 2.1 months (95% CI: 1.5, 2.7) for CYRAMZA vs. 1.3 months (95% CI: 1.3, 1.4) for placebo. HR: 0.48 (95% CI: 0.38, 0.62), p<0.001.
Locally advanced/metastatic gastric or GEJ adenocarcinoma (CYRAMZA + paclitaxel vs. Placebo + paclitaxel)	Overall Survival (OS)	Stratified log-rank	Study duration: 1–28 months	N=665 (CYRAMZA: 330; Placebo: 335)	Median OS: 9.6 months (95% CI: 8.5, 10.8) for CYRAMZA vs. 7.4 months (95% CI: 6.3, 8.4) for placebo. HR: 0.81 (95% CI: 0.68, 0.96), p=0.017.
	Progression-Free Survival (PFS)	Stratified log-rank	Study duration: 1–28 months	N=665 (CYRAMZA: 330; Placebo: 335)	Median PFS: 4.4 months (95% CI: 4.2, 5.3) for CYRAMZA vs. 2.9 months (95% CI: 2.8, 3.0) for placebo. HR: 0.64 (95% CI: 0.54, 0.75), p<0.001.
	Objective Response Rate (ORR)	Stratified CMH test	Study duration: 1–28 months	N=665 (CYRAMZA: 330; Placebo: 335)	ORR: 28% (95% CI: 23, 33) for CYRAMZA vs. 16% (95% CI: 13, 20) for placebo. p<0.001. Median DoR: not reported.

Approved Product Analysis: Enhertu

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
HER2+ locally advanced/metastatic gastric/GEJ adenocarcinoma (ENHERTU vs. chemotherapy)	Overall Survival (OS)	Kaplan-Meier, stratified Cox	Study duration: 24 months	N=188 (ENHERTU: 126; Chemo: 62)	Median OS: 12.5 months (95% CI: 9.6, 14.3) for ENHERTU vs. 8.4 months (95% CI: 6.9, 10.7) for chemo. HR: 0.59 (95% CI: 0.39, 0.88), p=0.0097.
	Progression-Free Survival (PFS)	Kaplan-Meier, stratified Cox	Study duration: 24 months	N=188 (ENHERTU: 126; Chemo: 62)	Median PFS: 5.6 months (95% CI: 4.3, 6.9) for ENHERTU vs. 3.5 months (95% CI: 2.0, 4.3) for chemo. HR: 0.47 (95% CI: 0.31, 0.71).
	Objective Response Rate (ORR)	Stratified CMH	Study duration: 24 months	N=188 (ENHERTU: 126; Chemo: 62)	ORR: 40.5% (95% CI: 31.8, 49.6) for ENHERTU vs. 11.3% (95% CI: 4.7, 21.9) for chemo. p<0.0001. Complete response: 7.9% (ENHERTU) vs. 0% (chemo).
	Duration of Response (DoR)	Kaplan-Meier	Study duration: 24 months	Responders: ENHERTU: 51; Chemo: 7	Median DoR: 11.3 months (95% CI: 5.6, not reached) for ENHERTU vs. 3.9 months (95% CI: 3.0, 4.9) for chemo.

Analysis of Failed for Stomach Cancer Over the Last 10 Years

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure	Trend Analysis
Matuzumab	NCT00101138	Lack of efficacy in Phase II trials for advanced gastric cancer.	Highlights challenges in targeting EGFR in gastric cancer, indicating potential pathway resistance.
Lapatinib	NCT00680901	Failed to meet primary endpoint of improved overall survival in Phase III trials for HER2-positive gastric cancer.	Suggests complexities in HER2 inhibition and the need for combination strategies.
Trastuzumab Emtansine	NCT01641939	Did not achieve primary endpoint in Phase II/III GATSBY trial for HER2-positive advanced gastric cancer.	Indicates limitations of antibody-drug conjugates in this context.
Cetuximab	NCT00450203	No survival benefit observed in Phase III trials for advanced gastric cancer.	Reflects difficulties in effectively targeting EGFR in gastric cancer.
Regorafenib	NCT01913639	Phase III INTEGRATE II study terminated due to lack of efficacy in advanced gastric cancer.	Emphasizes challenges in using multikinase inhibitors for gastric cancer treatment.

Unique Failure Points in Stomach Cancer Clinical Trials

1. Heterogeneity of Tumor Biology

Case Example : Variability in HER2 expression levels leading to inconsistent responses to HER2-targeted therapies.

Solution: Implement comprehensive biomarker profiling to select appropriate patient subgroups.

2. Geographic and Ethnic Variations

Case Example : Differences in genetic mutations and treatment responses between Asian and Western populations.

Solution: Design trials with diverse populations and consider regional genetic differences in study design.

3. Inadequate Patient Stratification

Case Example : Inclusion of patients without specific biomarkers, diluting potential treatment effects.

Solution: Utilize precise inclusion criteria based on molecular characteristics to enhance trial outcomes.

4. High Rate of Early Disease Progression

Case Example : Rapid progression in advanced stages leading to high dropout rates and insufficient data.

Solution: Employ adaptive trial designs and early interim analyses to adjust protocols as needed.

Safety Concerns

1. **Systemic Toxicities Across Modalities:**
   - Risk of malnutrition exacerbated by chemotherapy, surgery, or combined treatments.
   - Cumulative fatigue and quality-of-life reductions from multimodal therapies.
2. **Psychological and Emotional Impact:**
   - High rates of anxiety and depression due to treatment side effects and disease prognosis.
   - Management: Access to mental health professionals, peer support groups, and psychological counseling.
3. **Risk in Older Adults:**
   - Older patients often have comorbidities, reduced organ reserve, and a higher risk of adverse events.
   - Management: Comprehensive geriatric assessments and tailored treatment protocols to balance efficacy and safety.

Standard of Care Treatment Options

1. Surgery:

Approach: Surgery is the cornerstone for potentially curative treatment in resectable stomach cancer. Procedures include partial or total gastrectomy with D2 lymph node dissection.
Safety Concerns:

- Postoperative complications such as infections, bleeding, and anastomotic leaks.
- Nutritional deficiencies due to partial or complete removal of the stomach, resulting in malabsorption.
- Delayed gastric emptying and changes in bowel habits.

Management: Enhanced Recovery After Surgery protocols, close monitoring for complications, and nutritional support, including vitamin supplementation.

2. Chemotherapy:

Common Regimens: Perioperative chemotherapy using drugs like fluoropyrimidines (e.g., 5-FU, capecitabine) and platinum agents (e.g., cisplatin, oxaliplatin). Palliative chemotherapy is used for advanced stages.
Safety Concerns:

- Acute Toxicities: Nausea, vomiting, fatigue, and diarrhea.
- Chronic Effects: Myelosuppression leading to anemia, leukopenia, and increased infection risk. Neurotoxicity, especially with platinum-based therapies.
- Organ-Specific Damage: Nephrotoxicity with cisplatin and cardiotoxicity with agents like fluoropyrimidines.

Management: Prophylactic antiemetics, dose modifications for toxicity, hydration protocols, and granulocyte colony-stimulating factors (G-CSFs) for myelosuppression.

3. Radiation Therapy:

Role: Often used in conjunction with chemotherapy for locally advanced disease or in postoperative settings to reduce recurrence risk.
Safety Concerns:

- Acute Effects: Nausea, vomiting, and esophagitis leading to swallowing difficulties.
- Late Effects: Fibrosis, bowel obstruction, and radiation-induced secondary malignancies.
- Organ Damage: Collateral damage to surrounding organs, such as the liver, pancreas, and intestines.

4. Targeted Therapy:

Approved Agents: HER2-targeted therapy (trastuzumab) and VEGFR2 inhibitors (ramucirumab) for specific molecular subtypes.
Safety Concerns:

- Trastuzumab: Cardiotoxicity, including reduced left ventricular ejection fraction (LVEF).
- Ramucirumab: Hypertension, proteinuria, and bleeding risks.
- EGFR Inhibitors: Rash, diarrhea, and electrolyte imbalances.

Management: Regular cardiac monitoring for HER2-targeted therapies, antihypertensive treatment for VEGFR2 inhibitors, and dermatological care for EGFR-related toxicities.

INGENŪ CRO

Enhancing Clinical Trial Protocols for Stomach Cancer

Improving clinical trial protocols for Stomach Cancer is pivotal to advancing our understanding and treatment. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Adaptive Trial Designs:

Enable protocol modifications based on interim results to improve efficiency and success rates.

Use seamless Phase II/III trials to reduce delays.

2. Biomarker-Driven Approaches:

Leverage molecular profiling to identify and select patients likely to benefit, enhancing response rates and reducing heterogeneity.

Develop companion diagnostic tools early in collaboration with diagnostic companies.

3. Enhanced Endpoints and Statistical Models:

Incorporate composite endpoints like OS, PFS, and QoL.

Use innovative statistical methods like Bayesian models for flexibility in evaluating treatment effects.

4. Comprehensive Safety Monitoring:

Utilize real-time safety data collection and pharmacovigilance integration to detect and manage adverse events early.

Establish DSMBs for consistent oversight during trials.

5. Regulatory Engagement:

Maintain early and ongoing communication with the FDA through pre-IND meetings and adaptive pathways.

Align trial protocols with regulatory expectations to streamline approval.

6. Global Considerations:

Include diverse geographic and ethnic populations to ensure global applicability and address genetic variability.

Conduct region-specific subgroup analyses for tailored insights.

7. Patient-Centric Trial Designs:

Adopt hybrid or decentralized models to reduce patient burden and improve retention.

Incorporate patient-reported outcomes to assess tolerability.

8. Digital and Technological Integration:

Use AI and wearable devices to enhance trial efficiency, predict responses, and monitor real-time data.

Notable Key Opinion Leaders in Stomach Cancer Research

Name	Specialty	Designation	Location	Brief Bio
Michael J Millward (MBBS, FRACP)	Medical Oncology	Professor, University of Western Australia	Western Australia, Australia	Professor Millward is a distinguished medical oncologist specializing in clinical cancer research. At UWA, he leads initiatives aimed at advancing cancer treatment methodologies. His clinical practice at Sir Charles Gairdner Hospital focuses on providing comprehensive care to cancer patients. Professor Millward has been instrumental in numerous clinical trials and has contributed significantly to oncology research. He has received recognition for his work, including awards from professional oncology societies.
Niall C Tebbutt (MBBS, FRACP)	Medical Oncology	Director, Olivia Newton John Cancer Research Institute	Victoria, Australia	Professor Tebbutt is a leading figure in medical oncology, overseeing clinical and research programs at the Olivia Newton-John Cancer Research Institute. His work focuses on translational research, aiming to bring laboratory discoveries into clinical practice to improve patient outcomes. Professor Tebbutt has been recognized for his contributions to oncology with several awards and has published extensively in peer-reviewed journals.
Hui K Gan (MBBS, FRACP)	Oncology; Medical Oncology	Director, Austin Health	Victoria, Australia	Dr. Gan leads the oncology department at Austin Health, where he focuses on integrating clinical care with research. He has a particular interest in early-phase clinical trials and the development of novel therapeutics for cancer treatment. Dr. Gan has been acknowledged for his contributions to oncology through various professional accolades and has authored numerous research articles.
Christos S Karapetis (MBBS, FRACP)	Medical Oncology	Professor, Flinders University	South Australia, Australia	Professor Karapetis is renowned for his work in clinical oncology and cancer research. At Flinders University and Flinders Medical Centre, he leads clinical research programs focusing on gastrointestinal cancers, including gastric cancer. His research has significantly influenced treatment protocols and patient care standards. Professor Karapetis has received multiple awards for his contributions to oncology and has an extensive publication record.
Paul De Souza (MBBS, PhD, FRACP)	Medical Oncology	Professor, Western Sydney University	New South Wales, Australia	Professor De Souza is a leading medical oncologist and academic, heading the medical oncology department at Western Sydney University. His research interests include the development of new cancer therapies and improving clinical outcomes for patients with gastrointestinal cancers. Professor De Souza has been recognized for his contributions to medical education and oncology research through various awards and honors.

References

- Digklia, A., & Wagner, A. D. (2016). Advanced gastric cancer: Current treatment landscape and future perspectives. World Journal of Gastroenterology, 22(8), 2403–2414.
- Dudzińska, E., & Sitarz, R. (2024). Gastric cancer: An up-to-date review with new insights into early-onset gastric cancer. Cancers, 16(18), 3163.
- Figueiredo, C., Garcia-Gonzalez, M. A., & Machado, J. C. (2013). Molecular pathogenesis of gastric cancer. Helicobacter, 18(S1), 28–33.
- Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., … & Yoon, H. H. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. The Lancet, 398(10294), 27–40.
- Li, H., Shen, M., & Wang, S. (2024). Current therapies and progress in the treatment of advanced gastric cancer. Frontiers in Oncology, 14.
- Lorenzen, S., & Lordick, F. (2022). Immunotherapy in gastric cancer. Expert Review of Anticancer Therapy, 22(7), 711–722.
- Salah, H., & Abdelrahim, M. (2022). Recent trends and advancements in the diagnosis and management of gastric cancer. Cancers, 14(22), 5615.
- Sitarz, R., Skierucha, M., Mielko, J., Offerhaus, G. J., Maciejewski, R., & Polkowski, W. P. (2018). Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Management and Research, 10, 239–248.
- Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. T., & Lordick, F. (2020). Gastric cancer. The Lancet, 396(10251), 635–648.
- Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K., & Prenen, H. (2016). Gastric cancer. The Lancet, 388(10060), 2654–2664.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com